BR9809694A - Processo e composição para administração de taxanos oralmente a pacientes humanos - Google Patents

Processo e composição para administração de taxanos oralmente a pacientes humanos

Info

Publication number
BR9809694A
BR9809694A BR9809694-0A BR9809694A BR9809694A BR 9809694 A BR9809694 A BR 9809694A BR 9809694 A BR9809694 A BR 9809694A BR 9809694 A BR9809694 A BR 9809694A
Authority
BR
Brazil
Prior art keywords
taxane
human patients
administered
oral
orally
Prior art date
Application number
BR9809694-0A
Other languages
English (en)
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of BR9809694A publication Critical patent/BR9809694A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"PROCESSO E COMPOSIçãO PARA ADMINISTRAçãO DE TAXANOS ORALMENTE A PACIENTES HUMANOS"<D>. Agentes antineoplásticos de taxano que até aqui exibiram biodisponibilidade oral fraca ou não existente são administrados oralmente a pacientes humanos sofrendo de estados de doença em resposta a taxano e são tornados suficientemente biodisponíveis para atingir os níveis sang³íneos terapêuticos. Em uma modalidade preferida, o taxano, preferencialmente paclitaxel, é co-administrado ao paciente com um agente de melhoramento oral ciclosporina, preferencialmente ciclosporina A. Por um processo preferido, uma dose de melhorador oral é administrada a aproximadamente 0,5-72 horas antes do taxano e uma segunda dose do melhorador é administrada imediatamente antes, junto com ou imediatamente depois do taxano. é também fornecido um processo para tratar pacientes humanos sofrendo de estados de doença em resposta a taxano, assim como um processo para fornecer tal tratamento enquanto previne ou reduz a hipersensibilidade e as reações alérgicas sem a necessidade de pré-medicação.
BR9809694-0A 1997-05-27 1998-04-22 Processo e composição para administração de taxanos oralmente a pacientes humanos BR9809694A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27
PCT/US1998/007776 WO1998053811A1 (en) 1997-05-27 1998-04-22 Method and compositions for administering taxanes orally to human patients

Publications (1)

Publication Number Publication Date
BR9809694A true BR9809694A (pt) 2000-10-03

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809694-0A BR9809694A (pt) 1997-05-27 1998-04-22 Processo e composição para administração de taxanos oralmente a pacientes humanos

Country Status (22)

Country Link
EP (1) EP0994706B1 (pt)
JP (1) JP2002500667A (pt)
KR (1) KR100615783B1 (pt)
CN (2) CN1261275A (pt)
AR (1) AR012731A1 (pt)
AT (1) ATE308365T1 (pt)
AU (1) AU7130098A (pt)
BR (1) BR9809694A (pt)
CA (1) CA2290446C (pt)
CZ (1) CZ9904244A3 (pt)
DE (1) DE69832173T2 (pt)
DK (1) DK0994706T3 (pt)
ES (1) ES2247690T3 (pt)
HU (1) HUP0003546A3 (pt)
IL (2) IL132992A0 (pt)
NO (1) NO995812L (pt)
PL (1) PL337064A1 (pt)
RU (1) RU2205005C2 (pt)
SK (1) SK157599A3 (pt)
UA (1) UA74767C2 (pt)
WO (1) WO1998053811A1 (pt)
ZA (1) ZA984268B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
SK182599A3 (en) * 1997-06-20 2000-07-11 Baker Norton Pharma Soluble prodrugs of paclitaxel
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU4955200A (en) 1999-05-17 2000-12-05 Cancer Research Ventures Limited A method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs
RU2236226C2 (ru) * 1999-06-18 2004-09-20 Бейкер Нортон Фармасьютикалз, Инк. Пероральные фармацевтические композиции, содержащие таксаны, и способы лечения с их применением
MXPA02004164A (es) * 1999-10-27 2002-10-17 Baker Norton Pharma Metodo y composiciones para administrar taxanos por via oral a pacientes humanos.
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MXPA03006404A (es) * 2001-01-18 2004-12-02 Upjohn Co Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
SI1372636T1 (sl) * 2001-02-28 2006-12-31 Bristol Myers Squibb Co Metronomsko odmerjanje taksanov za inhibiranje tumorske rasti
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
JP2008501708A (ja) * 2004-06-04 2008-01-24 スミスクライン ビーチャム （コーク） リミテッド がんの治療方法
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
AU2010256677A1 (en) * 2009-06-02 2012-01-12 Nikan Pharmaceuticals, Llc Antagonism of human formyl peptide receptor for treatment of disease
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
BR112023018826A2 (pt) * 2021-03-17 2024-03-12 Dompe Farm Spa Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
SG45403A1 (en) * 1991-01-11 1998-01-16 Glaxo Lab Sa Acridine derivatives
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
HU222496B1 (hu) * 1994-07-26 2003-07-28 Indena S.P.A. Félszintetikus taxánszármazékok, eljárás ezek előállítására, valamint ezeket tartalmazó gyógyászati készítmények
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
CA2258556A1 (en) * 1996-06-17 1997-12-24 Julian Stanley Kroin Drug resistance and multidrug resistance modulators
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1067908B9 (en) * 1998-04-01 2007-01-24 Jagotec Ag Taxane microemulsions

Also Published As

Publication number Publication date
UA74767C2 (en) 2006-02-15
HK1026637A1 (en) 2000-12-22
AR012731A1 (es) 2000-11-08
IL132992A0 (en) 2001-03-19
WO1998053811A1 (en) 1998-12-03
DE69832173T2 (de) 2006-08-03
JP2002500667A (ja) 2002-01-08
NO995812D0 (no) 1999-11-26
ATE308365T1 (de) 2005-11-15
HUP0003546A3 (en) 2002-12-28
CA2290446A1 (en) 1998-12-03
CA2290446C (en) 2008-01-29
RU2205005C2 (ru) 2003-05-27
KR20010013025A (ko) 2001-02-26
SK157599A3 (en) 2002-10-08
ZA984268B (en) 1999-06-23
DK0994706T3 (da) 2006-03-06
DE69832173D1 (de) 2005-12-08
EP0994706A1 (en) 2000-04-26
HUP0003546A2 (hu) 2002-11-28
EP0994706A4 (en) 2001-05-16
IL132992A (en) 2006-08-20
CN1261275A (zh) 2000-07-26
ES2247690T3 (es) 2006-03-01
CN1550231A (zh) 2004-12-01
AU7130098A (en) 1998-12-30
CZ9904244A3 (cs) 2001-10-17
PL337064A1 (en) 2000-07-31
KR100615783B1 (ko) 2006-08-25
NO995812L (no) 2000-01-25
EP0994706B1 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
BR9607066A (pt) Método, composições e conjuntos para aumentar a biodisponibilidade oral de agentes farmacêuticos
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
RU2012106620A (ru) Комбинации и способы введения терапевтических средств и комбинированной терапии
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
CA2290446A1 (en) Method and compositions for administering taxanes orally to human patients
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
KR970061244A (ko) 치매 치료용 약학 조성물
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
RU99128033A (ru) Способ и композиции для перорального введения таксанов
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
CA2519789A1 (en) Aplidine for multiple myeloma treatment
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1769 DE 20041130 POR TER SIDO APRESENTADA PAPELETA DE ESCLARECIMENTO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.